Pfizer and Family Health International (FHI) Join Forces
  in the Fight against HIV/AIDS in Guangxi
Share :  
  • Nanning    March 31, 2006

  • Today, Pfizer and Family Health International (FHI) jointly announced the official launch of a new collaborative HIV/AIDS training program in partnership with the Guangxi Center for Disease Control & Prevention (CDC) in Nanning, the capital city of Guangxi Zhuang Autonomous Region.

    In line with an agreement signed in 2005, Pfizer funded grants totaling one million Yuan (US$125,000) to FHI. The Pfizer grants have facilitated multiple HIV/AIDS initiatives to be conducted in several locations in China, including a partnership initiative with the Guangxi CDC to establish a healthcare provider HIV/AIDS training program in Guangxi. The training program is tailored to enhance diagnosis and treatment capabilities of over 100 first-line healthcare providers in community hospitals across Guangxi. Additionally, the grant will support FHI in providing continuous support and training at hospitals in Pingxiang and Ningming treating AIDS patients. FHI will recruit both overseas and local experts to assist healthcare providers strengthening their diagnosis and treatment of HIV/AIDS. A select group of healthcare providers will also be sponsored to study at a training course in Thailand.

    "The training partnership program is a part of Pfizer's support in advancing government priorities in HIV/AIDS care," said Ms. Paula Luff, Senior Director of Corporate Philanthropy, Pfizer Inc. "We strongly believe that the training will not only develop better qualified healthcare providers, but will also benefit patients living with HIV/AIDS by offering earlier diagnosis and improved care."

    "With the support of Pfizer, we are able to provide quality and value-added training for Guangxi healthcare providers. We believe that this partnership between the government, industry and NGOs will create a successful model for training healthcare providers in China," commented Dr. Cheng Feng, County Director of FHI.

    In recent years, China has seen an increase in HIV/AIDS transmission rates from high risk individuals to the general population. A recent HIV/AIDS report revised the count to approximately 650,000 HIV/AIDS-infected individuals in China. Last March, Vice Premier Wu Yi stated in a nationwide HIV/AIDS conference, "To succeed in AIDS prevention and treatment is not only an unshakable obligation of the Chinese government but also the common responsibility of society as a whole, including business."

    Deputy Director Chen Jie from Guangxi CDC and other relevant government officials were also present at the opening ceremony.

    Pfizer is a global research-based company, discovering, developing, manufacturing and marketing leading prescription medicines for humans and animals and many of the world's best-known consumer brands. To date, Pfizer has invested more than US$500 million in China. With an unequalled product portfolio, Pfizer China remains a strong leader in the therapeutic areas of cardiovascular disease, endocrinology, neuroscience, arthritis and other inflammatory diseases, infectious disease, urology and oncology. For more information, please visit http://www.pfizer.com.cn.

    Formed in 1971, FHI is a leader among nonprofit international public health organizations, managing research and field activities in more than 70 countries to meet the public health needs of some of the world's most vulnerable people.

Text SizeAAA